Announcements Trials
Browse Landscape

Phase

Phase 3 7Phase 2 5Phase 1 3Phase NA 1Phase 4 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Papillomavirus Infections 4Uterine Cervical Dysplasia 3Uterine Cervical Neoplasms 1Inflammatory Bowel Diseases 1Crohn Disease 1Colitis, Ulcerative 1Acquired Immunodeficiency Syndrome 1

Interventions

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 6human papillomavirus vaccine, L1 type 16, 18 4Vaccines 3fluciclovine F-18 2pegylated granulocyte colony-stimulating factor 1halofantrine 1ferrous fumarate 1epoetin beta 1apatinib 1Tobacco Use Cessation Devices 1TachoSil 1Surveys and Questionnaires 1Radiotherapy 1Quality of Life 1Psychiatric Rehabilitation 1Polymerase Chain Reaction 1Patient Navigation 1Papillomavirus Vaccines 1Mindfulness 1Indocyanine Green 1Human Papillomavirus Recombinant Vaccine nonavalent 1Hepatitis B Vaccines 1Gonadal Steroid Hormones 1Gene Expression Profiling 1Engerix-B 1Early Intervention, Educational 1Counseling 1Cognitive Behavioral Therapy 1Cisplatin 1Bupropion 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Uterine Cervical Neoplasms × Papillomavirus Vaccines × Clear all
NCT03629886 2024-03-15

Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study

GlaxoSmithKline

Phase 4 Completed
6,051 enrolled 11 charts
Gynecologic

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡